PRESTIGE CONSUMER HEALTHCARE INC. (PBH) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 10.45M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 2.01B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 4.57B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $10.45M | $2.01B | (m) | (m) | $4.57B | (m) |
| 2026-03-31 | (m) | (m) | $0.00 | $993.95M | (m) | (m) | $3.49B | (m) |
| 2024-12-31 | (m) | (m) | (m) | $1.00B | (m) | (m) | $3.33B | (m) |
| 2024-09-30 | (m) | (m) | (m) | $1.06B | (m) | (m) | $3.32B | (m) |
| 2024-06-30 | (m) | (m) | (m) | $1.10B | (m) | (m) | $3.31B | (m) |
| 2024-03-31 | (m) | (m) | (m) | $1.13B | (m) | (m) | $3.32B | (m) |
| 2023-12-31 | (m) | (m) | (m) | $1.21B | (m) | (m) | $3.34B | (m) |
| 2023-09-30 | (m) | (m) | (m) | $1.27B | (m) | (m) | $3.33B | (m) |
| 2023-06-30 | (m) | (m) | (m) | $1.33B | (m) | (m) | $3.35B | (m) |
| 2023-03-31 | (m) | (m) | (m) | $1.35B | (m) | (m) | $3.35B | (m) |
| 2022-12-31 | (m) | (m) | (m) | $1.44B | (m) | (m) | $3.75B | (m) |
| 2022-09-30 | (m) | (m) | (m) | $1.46B | (m) | (m) | $3.68B | (m) |
| 2022-06-30 | (m) | (m) | (m) | $1.49B | (m) | (m) | $3.68B | (m) |
| 2022-03-31 | (m) | (m) | (m) | $1.48B | (m) | (m) | $3.67B | (m) |
| 2021-12-31 | (m) | (m) | (m) | $1.55B | (m) | (m) | $3.66B | (m) |
| 2021-09-30 | (m) | (m) | $6.00M | $1.61B | (m) | (m) | $3.68B | (m) |
| 2021-06-30 | (m) | (m) | (m) | $1.55B | (m) | (m) | $3.56B | (m) |
| 2021-03-31 | (m) | (m) | (m) | $1.48B | (m) | (m) | $3.43B | (m) |
| 2020-12-31 | (m) | (m) | (m) | $1.55B | (m) | (m) | $3.47B | (m) |
| 2020-09-30 | (m) | (m) | (m) | $1.55B | (m) | (m) | $3.43B | (m) |
| 2020-06-30 | (m) | (m) | (m) | $1.62B | (m) | (m) | $3.45B | (m) |
| 2020-03-31 | (m) | (m) | (m) | $1.73B | (m) | (m) | $3.51B | (m) |
| 2019-12-31 | (m) | (m) | (m) | $1.70B | (m) | (m) | $3.46B | (m) |
| 2019-09-30 | (m) | (m) | (m) | $1.75B | (m) | (m) | $3.46B | (m) |
| 2019-06-30 | (m) | (m) | (m) | $1.78B | (m) | (m) | $3.46B | (m) |
| 2019-03-31 | (m) | (m) | (m) | $1.80B | (m) | (m) | $3.44B | (m) |
| 2018-12-31 | (m) | (m) | (m) | $1.84B | (m) | (m) | $3.67B | (m) |
| 2018-09-30 | (m) | (m) | (m) | $1.90B | (m) | (m) | $3.70B | (m) |
| 2018-06-30 | (m) | (m) | (m) | $1.99B | (m) | (m) | $3.77B | (m) |
| 2018-03-31 | (m) | (m) | (m) | $1.99B | (m) | (m) | $3.76B | (m) |
| 2017-12-31 | (m) | (m) | (m) | $2.05B | (m) | (m) | $3.90B | (m) |
| 2017-09-30 | (m) | (m) | (m) | $2.09B | (m) | (m) | $3.90B | (m) |
| 2017-06-30 | (m) | (m) | (m) | $2.15B | (m) | (m) | $3.90B | (m) |
| 2017-03-31 | (m) | (m) | (m) | $2.19B | (m) | (m) | $3.91B | (m) |
| 2016-12-31 | (m) | (m) | (m) | $1.42B | (m) | (m) | $2.81B | (m) |
| 2016-09-30 | (m) | (m) | (m) | $1.48B | (m) | (m) | $2.83B | (m) |
| 2016-06-30 | (m) | (m) | (m) | $1.58B | (m) | (m) | $2.88B | (m) |
| 2016-03-31 | (m) | (m) | (m) | $1.63B | (m) | (m) | $2.95B | (m) |
| 2015-12-31 | (m) | (m) | (m) | $1.45B | (m) | (m) | $2.64B | (m) |
| 2015-09-30 | (m) | (m) | (m) | $1.47B | (m) | (m) | $2.63B | (m) |
| 2015-06-30 | (m) | (m) | $8.53M | $1.51B | (m) | (m) | $2.64B | (m) |
| 2015-03-31 | (m) | (m) | (m) | $1.59B | (m) | (m) | $2.67B | (m) |
| 2014-12-31 | (m) | (m) | (m) | $1.64B | (m) | (m) | $2.68B | (m) |
| 2014-09-30 | (m) | (m) | $7.20M | $1.69B | (m) | (m) | $2.73B | (m) |
| 2014-06-30 | (m) | (m) | (m) | $969.56M | (m) | (m) | $1.85B | (m) |
| 2014-03-31 | (m) | (m) | (m) | $934.41M | (m) | (m) | $1.80B | (m) |
| 2013-12-31 | (m) | (m) | (m) | $981.51M | (m) | (m) | $1.86B | (m) |
| 2013-09-30 | (m) | (m) | (m) | $978.70M | (m) | (m) | $1.81B | (m) |
| 2013-06-30 | (m) | (m) | (m) | $953.25M | (m) | (m) | $1.74B | (m) |
| 2013-03-31 | (m) | (m) | (m) | $970.90M | (m) | (m) | $1.74B | (m) |
| 2012-12-31 | (m) | (m) | (m) | $1.00B | (m) | (m) | $1.73B | (m) |
| 2012-09-30 | (m) | (m) | (m) | $1.08B | (m) | (m) | $1.79B | (m) |
| 2012-06-30 | (m) | (m) | (m) | $1.10B | (m) | (m) | $1.75B | (m) |
| 2012-03-31 | (m) | (m) | (m) | $1.12B | (m) | (m) | $1.76B | (m) |
| 2011-12-31 | (m) | (m) | (m) | $429.63M | (m) | (m) | $1.05B | (m) |
| 2011-09-30 | (m) | (m) | (m) | $447.40M | (m) | (m) | $1.06B | (m) |
| 2011-06-30 | (m) | (m) | (m) | $464.17M | (m) | (m) | $1.05B | (m) |
| 2011-03-31 | (m) | (m) | (m) | $486.94M | (m) | (m) | $1.06B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |